Lowest Price Guaranteed
Pages
291
Last Updated
August 2026
View Count
5462
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Introduction to Transfection
6.3. Methods of Transfection
6.3.1. Virus Based Transfection
6.3.1.1. Types of Viral Transfection Vectors
6.3.1.1.1. Adeno-associated Virus-based Vectors
6.3.1.1.2. Adenovirus-based Vectors
6.3.1.1.3. Herpes Virus-based Vectors
6.3.1.1.4. Lentivirus-based Vectors
6.3.1.1.5. Retrovirus-based Vectors
6.3.2. Non-Virus Based Transfections
6.3.2.1. Chemical Methods based Transfection
6.3.2.1.1. Lipoplexes-based Transfection
6.3.2.1.2. Polyplexes-based Transfection
6.3.2.1.3. Lipo-polyplexes-based Transfection
6.3.2.1.4. Dendrimer-based Transfection
6.3.2.1.5. Cell Penetrating Peptide-based Transfection
6.3.2.2. Physical Method based Transfections
6.3.2.2.1. Electroporation-based Transfection
6.3.2.2.2. Gene Gun-based Transfection
6.3.2.2.3. Sonoporation-based Transfection
6.3.2.2.4. Microinjection-based Transfection
6.3.2.2.5. Magnetofection-based Transfection
6.4. Applications of Transfection
6.4.1. Advanced Therapeutic Medicinal Product Development
6.4.2. Gene Silencing
6.4.3. Generation of Stable Cell Lines
6.4.4. Large-scale Protein Production
6.4.5. Stem Cell Engineering
6.5. Future Perspective
7. MARKET LANDSCAPE: EUROPE NON-VIRAL TRANSFECTION REAGENTS
7.1. Chapter Overview
7.2. Europe Non-Viral Transfection Reagents: Overall Market Landscape
7.2.1. Analysis by Compatible Cell Type / Line
7.2.2. Analysis by Transfected Molecule
7.2.3. Analysis by Type of Transfection Carrier Used
7.2.4. Analysis by Type of Cell Culture
7.2.5. Analysis by Serum Compatibility
7.3. Europe Non-Viral Transfection Reagent Providers Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
8. MARKET LANDSCAPE: EUROPE ELECTROPORATION-BASED TRANSFECTION SYSTEMS
8.1. Chapter Overview
8.2. Europe Electroporation-based Transfection Systems: Overall Market Landscape
8.2.1. Analysis by Compatible Cell Type / Line
8.2.2. Analysis by Transfected Molecule
8.2.3. Analysis by Type of Waveform
8.2.4. Analysis by Pulse Voltage
8.3. Europe Electroporation-based Transfection System Providers Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Analysis by Leading Players
9. MARKET LANDSCAPE: EUROPE OTHER NON-VIRAL TRANSFECTION TECHNOLOGIES / SYSTEMS
9.1. Chapter Overview
9.2. Europe Other Non-Viral Transfection Technologies / Systems: Market Landscape
9.2.1. Analysis by Type of Offering
9.2.2. Analysis by Compatible Cell Type / Line
9.2.3. Analysis by Transfected Molecule
9.3. Europe Other Non-Viral Transfection Technologies / System Providers Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
10. COMPANY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Company Competitiveness Analysis
10.4.1. Non-Viral Transfection Reagent Providers based in Europe
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Technology Competitiveness Analysis: Electroporation-based Transfection Systems
11.4.1. Electroporation-based Transfection Systems Offered by Players based in Europe
11.5. Technology Competitiveness Analysis: Other Non-Viral Transfection Technology / Systems
11.5.1. Other Non-Viral Transfection Technologies / Systems Offered by Players based in Europe
12. COMPANY PROFILES
12.1. Chapter Overview
12.2. Biontex Laboratories*
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Non-Viral Transfection Reagents Portfolio
12.2.4. Recent Developments and Future Outlook
* Similar details are presented for other companies mentioned below (based on information in the public domain)
12.3. Lonza
12.4. MilliporeSigma
12.5. OZ Biosciences
12.6. PromoCell
12.7. QIAGEN
12.8. Sartorius
12.9. ScreenFect
13. POTENTIAL STRATEGIC PARTNERS
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Scope and Methodology
13.4. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in Europe
13.4.1. Most Likely Partners
13.4.2. Likely Partners
13.4.3. Less Likely Partners
13.4.4. Least Likely Partners
14. MARKET TRENDS ANALYSIS
14.1. Chapter Overview
14.2. Ex-vivo and In-vivo Therapy Trends
14.3. Viral and Non-Viral Vector Trends
15. PATENT ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Europe Non-Viral Transfection Reagents Market: Patent Analysis
15.3.1. Analysis by Patent Publication Year
15.3.2. Analysis by Type of Patent and Publication Year
15.3.3. Analysis by Patent Application Year
15.3.4. Analysis by Patent Jurisdiction
15.3.5. Analysis by CPC Symbols
15.3.6. Analysis by Type of Applicant
15.3.7. Leading Players: Analysis by Number of Patents
15.3.8. Leading Inventors: Analysis by Number of Patents
15.4. Patent Benchmarking Analysis
15.4.1. Analysis by Patent Characteristics
15.5. Patent Valuation
16. PUBLICATION ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Europe Non-Viral Transfection Reagents Market: Publication Analysis
16.3.1. Analysis by Year of Publication
16.3.2. Most Active Publisher: Analysis by Number of Publications
16.3.3. Key Journals: Analysis by Journal Impact Factor
16.3.4. Most Popular Journals: Analysis by Number of Publications
16.4. Prominent Copyright Holders: Analysis by Number of Publications
17. ROOTS ANALYSIS PRICING STRATEGY FRAMEWORK
17.1. Chapter Overview
17.2. Roots Analysis Framework
17.2.1. Methodology
17.2.2. Theoretical Framework and Price Evaluation Hypothesis
17.2.3. Results and Interpretation
17.2.3.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
17.2.3.2. Product Price Evaluation Matrix: Based on Compatible Cell Type / Line
17.2.3.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
17.2.3.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
17.2.3.5. Product Price Evaluation Matrix: Based on Type of Reagent
17.3. Concluding Remarks
18. MARKET IMPACT ANALYSIS
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
19. EUROPE NON-VIRAL TRANSFECTION REAGENTS MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Europe Non-Viral Transfection Reagents Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. EUROPE NON-VIRAL TRANSFECTION REAGENTS MARKET, BY TYPE OF NON-VIRAL TRANSFECTION METHOD
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Europe Non-Viral Transfection Reagents Market: Distribution by Type of Non-Viral Transfection Method
20.3.1. Europe Non-Viral Transfection Reagents Market for Chemical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.2. Europe Non-Viral Transfection Reagents Market for Physical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.3. Europe Non-Viral Transfection Reagents Market for Other Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. EUROPE NON-VIRAL TRANSFECTION REAGENTS MARKET, BY APPLICATION AREA
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Europe Non-Viral Transfection Reagents Market: Distribution by Application Area
21.3.1. Europe Non-Viral Transfection Reagents Market for Research Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.2. Europe Non-Viral Transfection Reagents Market for Clinical Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22. EUROPE NON-VIRAL TRANSFECTION REAGENTS MARKET, BY END-USER
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Europe Non-Viral Transfection Reagents Market: Distribution by End-User
22.3.1. Europe Non-Viral Transfection Reagents Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.2. Europe Non-Viral Transfection Reagents Market for Pharmaceutical and Biopharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.3. Europe Non-Viral Transfection Reagents Market for Contract Manufacturers, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.4. Europe Non-Viral Transfection Reagents Market for Other End-Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. CONCLUDING REMARKS
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Company A
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Former-Vice-President, Business Development and Partnerships
24.3. Company B
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Former Global Business Development Manager, Clinical Operations
24.4. Company C
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Researcher
24.5. Company D
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Chairman and Chief Executive Officer
24.6. Company E
24.6.1. Company Snapshot
24.6.2. Interview Transcript: Co-Founder and Chief Executive Officer
24.7. Company F
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Chief Scientific Officer and Executive Vice President of R&D
24.8. Company G
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Chief Scientific Officer
24.9. Company H
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Chief Scientific Officer
24.10. Company I
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Vice President of Cell Therapy Process Development
24.11. Company J
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Group Leader of R&D Transfection, and Director and Senior Product Manager
24.12. Company K
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Director, Senior Product Manager
24.13. Company L
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Senior Vice President of Technical Applications
24.14. Company M
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Head of Transfection R&D
25. APPENDIX I: TABULATED DATA
26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS